Every Form 4 that aTyr Pharma, Inc. (ATYR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ATYR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATYR filings page.
aTyr Pharma director Paul Schimmel reported an open-market purchase of 100,000 shares of aTyr Pharma common stock on May 27, 2026 at a weighted average price of $0.4963 per share.
According to the filing, these shares were bought in multiple trades between $0.4907 and $0.50 per share and are held indirectly through entities associated with Schimmel as noted in the footnotes.
aTyr Pharma director Timothy Coughlin received a compensatory stock option grant, giving him the right to acquire 50,000 shares of common stock. The option has an exercise price of $0.95 per share and expires on May 11, 2036.
According to the company’s non-employee director compensation policy, the option vests in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as Coughlin continues to serve on the board. After this grant, he holds stock options covering 50,000 shares directly.
aTYR Pharma director Eric Benevich received a new stock option grant. On May 11, 2026, he was awarded options to buy 50,000 shares of aTYR Pharma common stock at an exercise price of $0.95 per share. These options were granted under the company’s non-employee director compensation policy.
The option vests in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, provided he continues serving on the Board of Directors. Following this grant, he holds 50,000 stock options directly.
aTyr Pharma director Jane A. Gross received a grant of stock options covering 50,000 shares of Common Stock. The options have an exercise price of $0.95 per share and were awarded at no upfront cost as a compensation grant.
The options vest in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as Gross continues to serve on the Board. After this grant, she holds 50,000 stock options directly according to the filing.
aTYR PHARMA INC director Svetlana Lucas received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $0.95 per share and expire on May 11, 2036.
The grant was made under the company’s non-employee director compensation policy. The options vest in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as she continues serving on the board. This is a compensation-related award rather than an open-market transaction.
aTYR Pharma director Sara Zaknoen received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $0.95 per share and were awarded with no purchase price at grant. They vest in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as she continues serving on the board. After this award, she holds options for 50,000 shares directly.
aTYR Pharma reported that director Paul Schimmel received a grant of stock options as part of the company’s non-employee director compensation policy. The award covers 50,000 options to buy common stock at an exercise price of $0.95 per share, expiring on May 11, 2036.
The option vests in full on the earlier of May 11, 2027 or the company’s 2027 annual stockholders’ meeting, conditioned on his continued board service. Following this grant, Schimmel holds 50,000 stock options directly, and the filing does not show additional derivative holdings.
aTyr Pharma President and CEO Sanjay Shukla reported routine equity compensation activity. On February 3, 2026, 10,375 restricted stock units granted on February 3, 2022 vested and converted into the same number of common shares on a one-for-one basis.
On February 4, 2026, he sold 3,745 common shares at $0.976 per share to satisfy tax withholding obligations tied to this vesting. After these transactions, Shukla directly owned 153,553 shares of aTyr Pharma common stock. The RSU award vests in four equal annual installments from February 3, 2023 through February 3, 2026 and can vest earlier if he is terminated without cause following a change of control.
aTyr Pharma’s Chief Financial Officer, Jill Marie Broadfoot, reported routine equity compensation activity and a small share sale. On February 3, 2026, 3,750 restricted stock units vested and converted into the same number of common shares, originally granted on February 3, 2022.
On February 4, 2026, she sold 1,558 common shares at $0.976 per share to cover tax withholding obligations related to this RSU vesting. After these transactions, she directly held 37,296 shares of aTyr Pharma common stock, and no restricted stock units from this grant remained outstanding.
aTyr Pharma’s general counsel, Nancy Denyes, reported routine equity compensation activity and a small share sale. On February 3, 2026, 2,687 restricted stock units granted in 2022 vested and converted into the same number of common shares. On February 4, 2026, she sold 1,118 shares at $0.9761 per share to cover tax withholding tied to this RSU vesting. After these transactions, she directly owned 33,124 aTyr Pharma common shares.
aTyr Pharma Inc. reported an insider equity award to its President and CEO, Sanjay Shukla. On January 9, 2026, he was granted an employee stock option for 1,500,000 shares of common stock at an exercise price of $0.7127 per share. The Form 4 shows the transaction as acquired and held directly, with 1,500,000 derivative securities beneficially owned after the grant.
The option will vest in 36 equal monthly installments beginning February 9, 2026, and is expected to be fully exercisable by January 9, 2029. The award agreement also provides for accelerated vesting if Dr. Shukla is terminated without cause in connection with a change of control of the company.
aTyr Pharma’s Chief Financial Officer, Jill Marie Broadfoot, reported a grant of 412,500 Employee Stock Options on January 9, 2026. The options have an exercise price of $0.7127 per share and were granted at $0 cost, increasing her derivative holdings to 412,500 options.
According to the filing, these options vest in 36 equal monthly installments beginning February 9, 2026 and are scheduled to be fully exercisable on January 9, 2029, with potential accelerated vesting if she is terminated without cause following a change of control. After this grant, she beneficially owns 35,104 shares of common stock, including shares acquired through the company’s 2015 Employee Purchase Plan.
aTyr Pharma Inc.'s General Counsel, Nancy Denyes, reported a new equity award and current holdings. On January 9, 2026, she was granted 412,500 Employee Stock Options with an exercise price of $0.7127 per share. These options vest in 36 equal monthly installments beginning February 9, 2026, becoming fully exercisable on January 9, 2029, and are subject to accelerated vesting if she is terminated without cause in connection with a change of control of the company.
Following this grant, she beneficially owns 31,555 shares of aTyr Pharma common stock directly, which include 2,500 shares acquired on May 15, 2025 and 2,500 shares acquired on November 14, 2025 under the company’s 2015 Employee Purchase Plan.
aTYR Pharma (ATYR) director Paul Schimmel reported purchases totaling 1,000,000 common shares across 10/08/2025 and 10/09/2025 at weighted average prices of $0.898 and $0.9414 respectively. After these transactions the reporting person beneficially owned 1,413,023 shares indirectly through trusts and a prototype PSP vehicle. The filings note share purchase price ranges from $0.8536 to $0.95 for the first lot and $0.93 to $0.95 for the second, and identify ownership via the Paul Schimmel Prototype PSP and the Schimmel Revocable Trust.